Log in with your email address username.


[Correspondence] Clinical disease activity in the CALM study

Jean-Frederic Colombel and colleagues’ CALM study (Dec 23, 2017, p 2779),1 which investigated the effect of tight control management on Crohn’s disease, reported significantly better outcomes with tight control than with clinical medical management. Tight control consisted of prespecified therapy escalation if a patient’s Crohn’s disease activity index (CDAI) was at least 150, or if they had elevated C-reactive protein or calprotectin, and resulted in significantly better mucosal healing (and clinical remission) than did therapy escalation based on clinical symptoms alone.